anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Hepatosplenic Schistosomiasis 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prosthetic mesh placement for the prevention of parastomal herniation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Procedure On Rectum 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Procedure On Colon 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy
1. Infant 1 to 23 mo 2. Birth to 1 mo 3. Kasai Procedure 4. Intrahepatic Biliary Atresia
Provide patient population that should be included in the study
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Crohn's Disease 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for paracetamol (acetaminophen) overdose
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Accidental Paracetamol Overdose 9. Birth to 1 mo 10. Intentional Paracetamol Overdose 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Feed thickener for infants up to six months of age with gastro‐oesophageal reflux
1. Neonate 2. Term infant (37-41 weeks) 3. Gastroesophageal Reflux Disease 4. Birth to 1 mo
Provide patient population that should be included in the study
Laparoscopic versus open resection for sigmoid diverticulitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Diverticulitis Of Sigmoid Colon 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Proton pump inhibitors for functional dyspepsia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Nonulcer Dyspepsia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Closure methods of the appendix stump for complications during laparoscopic appendectomy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Laparoscopic Surgery 4. Adult 19-44 years 5. Child 6-12 years 6. Appendectomy 7. Middle Aged 45-64 years 8. Infant 1 to 23 mo 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Diverticulitis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Intravenous Drug User 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Direct‐acting antivirals for chronic hepatitis C
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Hepatitis C 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Ursodeoxycholic acid for cystic fibrosis‐related liver disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Hepatic Encephalopathy 9. Birth to 1 mo 10. Liver cirrhosis 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Hepatorenal Syndrome 9. Birth to 1 mo 10. Liver cirrhosis 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Management for intussusception in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Ileocecal Intussusception 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral calorie supplements for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. End Stage Kidney Disease 5. Middle Aged 45-64 years 6. Peritoneal Dialysis 7. Young Adult 19-24 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Liver transplant
Provide patient population that should be included in the study
Deprescribing versus continuation of chronic proton pump inhibitor use in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Gastroesophageal Reflux Disease 6. Peptic Ulcer 7. Aged 65-79 years 8. Gastro-esophageal Reflux Disease With Esophagitis 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Clostridium Difficile Infection 5. Young Adult 19-24 years 6. Diarrhoea 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years 6. Hepatitis B
Provide patient population that should be included in the study
Mesh fixation with glue versus suture for chronic pain and recurrence in Lichtenstein inguinal hernioplasty
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Inguinal Hernia 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Polymer‐based oral rehydration solution for treating acute watery diarrhoea
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Diarrhoea 10. Dehydration 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Crohn's Disease 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Methods to decrease blood loss during liver resection: a network meta‐analysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Liver Excision 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Heated insufflation with or without humidification for laparoscopic abdominal surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Laparoscopic Surgery 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Procedure On Abdomen 8. Infant 1 to 23 mo 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Crohn's Disease In Remission 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Internal dressings for healing perianal abscess cavities
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Wound Drainage 11. Adolescent 13-18 years 12. Perianal Abscess
Provide patient population that should be included in the study
Osmotic and stimulant laxatives for the management of childhood constipation
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Constipation 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐tuberculous therapy for maintenance of remission in Crohn's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Crohn's Disease 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Epidural local anaesthetics versus opioid‐based analgesic regimens for postoperative gastrointestinal paralysis, vomiting and pain after abdominal surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Abdominal Wall Procedure 5. Young Adult 19-24 years 6. General Anesthesia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Aminosalicylates for induction of remission or response in Crohn's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Crohn's Disease 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Sequential versus standard triple first‐line therapy for Helicobacter pylori eradication
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Helicobacter Pylori Infection 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Booster dose vaccination for preventing hepatitis B
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Vaccinated 5. Infant 1 to 23 mo 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Hepatitis Viral Test Negative 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Healthy
Provide patient population that should be included in the study
Fasting for haemostasis in children with gastrointestinal bleeding
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Gastrointestinal Bleeding 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Pancreatic duct guidewire placement for biliary cannulation for the prevention of post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pancreatitis 6. Pancreatic Sphincterotomy By Endoscopic Retrograde Cholangiopancreatography 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Liver cirrhosis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Eradication therapy for peptic ulcer disease in Helicobacter pylori‐positive people
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Helicobacter Pylori Identification Test Positive 5. Young Adult 19-24 years 6. Peptic Ulcer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for necrotising pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Acute Necrotizing Pancreatitis 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Procedure On Abdomen 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for dysphagia in long‐term, progressive muscle disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Myotonic Dystrophy 6. Metabolic Myopathy 7. Oculopharyngeal Muscular Dystrophy 8. Oculopharyngodistal Myopathy 9. Congenital Myopathy 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Adult 19-44 years 13. Middle Aged 45-64 years 14. Young Adult 19-24 years 15. Birth to 1 mo 16. Duchenne Muscular Dystrophy 17. Inclusion Body Myositis
Provide patient population that should be included in the study
Glutamine for induction of remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Crohn's Disease 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Periodontal therapy as adjunctive treatment for gastric Helicobacter pylori infection
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Helicobacter Pylori Infection 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Gastric Infection 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Duodenum‐preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Pancreatitis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Pregabalin for decreasing pancreatic pain in chronic pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Pancreatitis 5. Young Adult 19-24 years 6. Chronic Abdominal Pain 7. Aged 65-79 years
Provide patient population that should be included in the study
Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Adult 19-44 years 8. Middle Aged 45-64 years 9. Liver Surgery 10. Upper Gastrointestinal Operation 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Pancreatic Surgery
Provide patient population that should be included in the study
Antibiotic prophylaxis for surgical site infection in people undergoing liver transplantation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Liver transplant 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Etrolizumab for induction of remission in ulcerative colitis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Ulcerative Colitis 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgery for complete (full‐thickness) rectal prolapse in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Complete Rectal Prolapse 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatment for dysphagia (swallowing difficulties) in hereditary ataxia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Hereditary Disease 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Friedreich's ataxia 10. Middle Aged 45-64 years 11. Spinocerebellar Ataxia 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Ataxia 15. Dysphagia
Provide patient population that should be included in the study
Laparoscopic fundoplication surgery versus medical management for gastro‐oesophageal reflux disease (GORD) in adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Gastroesophageal Reflux Disease 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Crohn's Disease In Remission 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Oral budesonide for induction of remission in ulcerative colitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Ulcerative Colitis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Noninvasive positive pressure ventilation for acute respiratory failure following upper abdominal surgery
1. Aged 80 and over 80+ years 2. Abdominal surgery 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Acute Respiratory Failure 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Preoperative inspiratory muscle training for postoperative pulmonary complications in adults undergoing cardiac and major abdominal surgery
1. Aged 80 and over 80+ years 2. Abdominal surgery 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Cardiac surgery 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for heartburn in pregnancy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Heartburn 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Type I interferons for induction of remission in ulcerative colitis
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Ulcerative Colitis 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Methotrexate for maintenance of remission in ulcerative colitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Ulcerative Colitis In Remission 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Ulcerative Colitis 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Post‐pyloric versus gastric tube feeding for preventing pneumonia and improving nutritional outcomes in critically ill adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Enteral nutrition 5. Young Adult 19-24 years 6. Critical Illness 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Plugs for containing faecal incontinence
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Faecal incontinence 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Chronic Liver Disease 5. Infant 1 to 23 mo 6. Upper Gastrointestinal Haemorrhage 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Multiple chronic conditions 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Disease Of Liver
Provide patient population that should be included in the study
Budesonide for induction of remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Crohn's Disease 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Water infusion versus air insufflation for colonoscopy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Colonoscopy 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Bleeding Gastric Varices 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Enteral nutrition formulations for acute pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acute pancreatitis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Endoscopic or surgical intervention for painful obstructive chronic pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Pain 5. Obstructive Chronic Pancreatitis 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Treatment for cryoglobulinemic and non‐cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Disease Related Peripheral Neuropathy 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Viral Hepatitis C 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Tranexamic acid for upper gastrointestinal bleeding
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Upper Gastrointestinal Hemorrhage 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Hepatitis B vaccination during pregnancy for preventing infant infection
1. Hepatitis Viral Test Negative 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Inflammatory Bowel Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Non‐nutritive sucking for gastro‐oesophageal reflux disease in preterm and low birth weight infants
1. Infant 1 to 23 mo 2. Gastroesophageal Reflux Disease 3. Birth to 1 mo 4. Low Birth Weight Infant 5. Preterm Infant
Provide patient population that should be included in the study
Epinephrine injection versus epinephrine injection and a second endoscopic method in high‐risk bleeding ulcers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Peptic Ulcer With Hemorrhage 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for treating postpartum constipation
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Postpartum 4. Young Adult 19-24 years 5. Constipation 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Budesonide for maintenance of remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Crohn's Disease In Remission 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Vedolizumab for induction and maintenance of remission in ulcerative colitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ulcerative Colitis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Methotrexate for induction of remission in refractory Crohn's disease
1. Adult 19-44 years 2. Crohn's Disease 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Antimicrobial drugs for treating cholera
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cholera 6. Aged 65-79 years
Provide patient population that should be included in the study
Antimicrobial prophylaxis for colorectal surgery
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Procedure On Rectum 5. Middle Aged 45-64 years 6. Procedure On Colon 7. Young Adult 19-24 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Oropharyngeal Dysphagia 6. Aged 65-79 years
Provide patient population that should be included in the study
Dopamine agents for hepatic encephalopathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hepatic Encephalopathy 6. Aged 65-79 years
Provide patient population that should be included in the study
Early versus delayed laparoscopic cholecystectomy for acute gallstone pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Gallstone Acute Pancreatitis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Abdominal lift for laparoscopic cholecystectomy
1. Aged 80 and over 80+ years 2. Laparoscopic Surgery 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Opioids for acute pancreatitis pain
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acute pancreatitis 5. Young Adult 19-24 years 6. Abdominal Pain 7. Aged 65-79 years
Provide patient population that should be included in the study
Laparoscopic repair for perforated peptic ulcer disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Peptic ulcer perforation 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Open Mesh versus non‐Mesh for groin hernia repair
1. Inguinal Hernia
Provide patient population that should be included in the study
Antioxidant supplementation for sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Sickle Cell Disease 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Nebuliser systems for drug delivery in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis
1. Adult 19-44 years 2. Child 6-12 years 3. Middle Aged 45-64 years 4. Cystic Fibrosis 5. Young Adult 19-24 years 6. Physiotherapy 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis
1. Cystic Fibrosis
Provide patient population that should be included in the study
Interventions for the long‐term prevention of hereditary angioedema attacks
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Hereditary angioedema 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Strategies for screening for familial hypercholesterolaemia in primary care and other community settings
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Familial Hypercholesterolemia 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Embolisation for pulmonary arteriovenous malformation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Pulmonary Arteriovenous Malformation 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Long‐acting inhaled bronchodilators for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Cystic Fibrosis 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Asthma 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Lung disorder 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Enzyme replacement therapy for infantile‐onset Pompe disease
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Generalized Glycogen Storage Disease Of Infants 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Beta‐blockers for preventing aortic dissection in Marfan syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Marfan's Syndrome 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Congenital Heart Disease 4. Infant 1 to 23 mo 5. Surgery 6. Birth to 1 mo 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐invasive ventilation for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Blood Coagulation Disorder 4. Young Adult 19-24 years 5. Menorrhagia 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Pneumococcal vaccines for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravenous alpha‐1 antitrypsin augmentation therapy for treating patients with alpha‐1 antitrypsin deficiency and lung disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Chronic Obstructive Pulmonary Disease 9. Alpha-1-antitrypsin Deficiency 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Enzyme replacement therapy for Anderson‐Fabry disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Fabry's Disease 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Cystic Fibrosis 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis‐related lung disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Influenza 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Mucopolysaccharidosis Type II 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐inflammatory drugs and analgesics for managing symptoms in people with cystic fibrosis‐related arthritis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Hypertrophic Osteoarthropathy 5. Infant 1 to 23 mo 6. Cystic Fibrosis 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Arthropathy Associated With Cystic Fibrosis 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Home versus hospital intravenous antibiotic therapy for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Charcot-marie-tooth Disease 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral steroids for long‐term use in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Cystic Fibrosis Pulmonary Exacerbation 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Congenital Heart Disease 4. Infant 1 to 23 mo 5. Surgery 6. Birth to 1 mo
Provide patient population that should be included in the study
Surgical interventions for treating pectus excavatum
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Pectus Excavatum 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Sodium channel blockers for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Vaccines for preventing influenza in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Cystic Fibrosis 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for promoting physical activity in people with cystic fibrosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Cystic Fibrosis 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Single‐incision sling operations for urinary incontinence in women
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Stress urinary incontinence 6. Mixed Incontinence 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgical approach to hysterectomy for benign gynaecological disease
1. Aged 80 and over 80+ years 2. Uterine fibroid 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Bleeding Between Periods 6. Young Adult 19-24 years 7. Hysterectomy 8. Aged 65-79 years 9. Menorrhagia 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Combined oral contraceptive pill for primary dysmenorrhoea
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Primary Dysmenorrhea 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgery for women with apical vaginal prolapse
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Disease Recurrence 5. Young Adult 19-24 years 6. Uterine Prolapse 7. Vaginal Vault Prolapse 8. Recurrent Disease 9. Stress urinary incontinence 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Statins for women with polycystic ovary syndrome not actively trying to conceive
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Polycystic Ovarian Syndrome
Provide patient population that should be included in the study
Gonadotropin‐releasing hormone analogues for endometriosis
1. Endometriosis
Provide patient population that should be included in the study
Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Detrusor overactivity 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Overactive Bladder Syndrome 7. Aged 65-79 years
Provide patient population that should be included in the study
Immediate versus delayed postpartum insertion of contraceptive implant and IUD for contraception
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Late Postpartum State 5. Early Postpartum State 6. Mid Postpartum State 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency
1. Adult 19-44 years 2. Premature ovarian insufficiency 3. Young Adult 19-24 years 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use
1. Pain 2. Intrauterine contraception in situ 3. Abnormal Uterine Bleeding
Provide patient population that should be included in the study
Medical methods for first trimester abortion
1. Adult 19-44 years 2. Pregnant 3. First Trimester Pregnancy 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Immediate versus delayed postabortal insertion of contraceptive implant
1. Abortion
Provide patient population that should be included in the study
Treatment for recurrent vulvovaginal candidiasis (thrush)
1. Vulvovaginal Candidiasis
Provide patient population that should be included in the study
Surgical interventions for the management of chronic pelvic pain in women
1. Chronic Pelvic Pain Syndrome
Provide patient population that should be included in the study
Levonorgestrel‐releasing intrauterine device (LNG‐IUD) for symptomatic endometriosis following surgery
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Surgery 4. Young Adult 19-24 years 5. Endometriosis 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Ultrasound‐guided transvaginal ovarian needle drilling for clomiphene‐resistant polycystic ovarian syndrome in subfertile women
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Young Adult 19-24 years 5. Clomiphene-resistant Polycystic Ovary Syndrome 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Pentoxifylline for the treatment of endometriosis‐associated pain and infertility  
1. Premenopausal State 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Subfertility 5. Young Adult 19-24 years 6. Endometriosis 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Medical abortion offered in pharmacy versus clinic‐based settings
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Selective oestrogen receptor modulators (SERMs) for endometriosis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Endometriosis 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Dopamine agonists for preventing ovarian hyperstimulation syndrome
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. In Vitro Fertilization 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome
1. Adult 19-44 years 2. Anovulation 3. In Vitro Fertilization 4. Young Adult 19-24 years 5. Polycystic Ovarian Syndrome 6. Direct Injection Of Sperm Into Cytoplasm Of The Oocyte 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Progestogens or progestogen‐releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy)
1. Uterine fibroid 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Pessaries (mechanical devices) for managing pelvic organ prolapse in women
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pelvic prolapse 6. Aged 65-79 years
Provide patient population that should be included in the study
Pre‐ and postsurgical medical therapy for endometriosis surgery
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Surgery 4. Young Adult 19-24 years 5. Endometriosis 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Laparoscopic surgery for endometriosis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Endometriosis 5. Adolescent 13-18 years